/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Uromigos
  2. Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?
Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

The Uromigos · May 30, 2026

Experts reveal a major disconnect between clinical trial Quality of Life (QoL) data and patient reality, calling for new patient-centric metrics.

Intermittent, In-Person QoL Surveys Miss Peak Toxicity Between Visits

Quality of Life data collected only during clinic visits fails to capture the patient's experience during their "off" weeks, which is often when they feel the worst. Accurate QoL assessment requires remote, high-frequency data collection to get a true picture of the treatment burden over time.

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients? thumbnail

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

The Uromigos·2 months ago

Standard Toxicity Grades (CTCAE) Obscure Life-Altering Patient Experiences

Over a third of low-grade (1-2) toxicities are considered "life-changing" by patients. CTCAE grades were designed for physician decision-making (e.g., is it safe to give the next dose?), not to capture the true, long-term impact on a patient's quality of life.

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients? thumbnail

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

The Uromigos·2 months ago

Clinical Trial Quality-of-Life Data is Skewed by "Survivorship Bias"

Quality of Life (QoL) data is often misleadingly positive because it primarily captures responses from patients doing well enough to complete forms. Patients who stop treatment due to severe toxicity or disease progression are systematically excluded, painting an incomplete and overly optimistic picture.

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients? thumbnail

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

The Uromigos·2 months ago

The True Quality of Life Impact of Cancer Treatment Emerges Post-Therapy

The most significant, lasting effects of treatment toxicities on quality of life often become most apparent *after* therapy has concluded. Clinical trials that stop collecting data shortly after treatment completion miss this crucial long-term impact, underestimating the true burden of side effects.

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients? thumbnail

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

The Uromigos·2 months ago

For Metastatic Patients, Disease Control Overrides Quality of Life Concerns

A patient's disease stage fundamentally changes their risk calculus. In the metastatic setting, where the primary goal is survival, patients willingly endure significant toxicity as long as their cancer is controlled. In the adjuvant (curative) setting, the long-term impact of that same toxicity becomes a more critical factor.

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients? thumbnail

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

The Uromigos·2 months ago

Major Surgical Events in Trials Mask Drug-Specific Quality of Life Impacts

When a clinical trial includes a major procedure like a cystectomy for all patients, its overwhelming effect on quality of life can completely obscure the subtler side effects of the drug being tested. The measurement tool ends up capturing the impact of the surgery, not the specific therapeutic intervention.

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients? thumbnail

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

The Uromigos·2 months ago

Patient Discontinuation Rates Reveal Treatment Tolerability Better Than Questionnaires

In clinical trials, patients "vote with their feet." High rates of discontinuing an optional (adjuvant) phase of treatment provide a clearer, real-world signal of toxicity and their personal risk-benefit analysis than formal Quality of Life surveys. Their actions speak louder than their written responses.

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients? thumbnail

Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

The Uromigos·2 months ago